The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.

Feb 10 (Reuters) - AstraZeneca forecast steady 2026 profit growth and a slower rise in sales on Tuesday, betting on demand for its cancer drugs while it boost its pipeline and invests in the U.S. and ...

Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...

China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S ...

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of ...

A woman says her family is trying to raise the £2,000-a-month costs in Guernsey for her grandmother's "last option" cancer ...

India, Feb. 10 -- In a special enforcement drive against spurious and substandard anticancer drugs, the Delhi Government ...

AstraZeneca forecast steady 2026 profit growth on Tuesday, betting on demand for its cancer drugs while it boosts its ...